INBX · Inhibrx Biosciences, Inc.

The thesis

Inhibrx Biosciences has a real but unfinished head-and-neck cancer case: the 8 September 2026 Phase 2 response lead for INBRX-106 (ordastobart) has to hold through fuller data and a larger HPV-positive trial before Phase 3 can start. The oral presentation at the European Society for Medical Oncology (ESMO) congress in Madrid on 25 October 2026 is the next test. The 8 September 2026 Form 8-K reported confirmed responses in 48.3% of evaluable patients on INBRX-106 plus pembrolizumab, versus 26.5% on pembrolizumab alone.

The narrative is maturing: the September results are public and the shares have stopped falling. The adjusted close was $92.76 on 8 October 2026 and $98.19 on 21 October 2026, with the 14-day relative strength index (RSI), a momentum gauge, at 50.4 after a reading of 24.5 on 8 October 2026. The company's 13 October 2026 press release confirmed the ESMO oral slot for 25 October 2026, 8:30 to 10:00 CET. The conference data, not the price recovery, decides whether the case advances.

Bullish and bearish views on Inhibrx Biosciences, Inc.

The bull case on Inhibrx Biosciences, Inc. (INBX), in brief: Randomized responses favor the combination. The bear case: The development timetable moved back.

Bull case

• Randomized responses favor the combination. The 8 September 2026 filing reported confirmed response rates of 48.3% versus 26.5% among 63 evaluable patients. Median progression-free survival, the time before disease progression or death, was 9.6 months versus 4.9 months at the 19 August 2026 data cutoff; the survival figures are interim.
• The HPV-positive subgroup points to a focused trial. The same filing reported response rates of 80.0% versus 33.3% in the human papillomavirus (HPV)-positive subgroup, and a plan to add about 50 HPV-positive patients before seeking Food and Drug Administration (FDA) alignment. The subgroup held 10 combination-arm and nine control-arm patients, so the sample is too small to size the effect.
• A full data set is due within days. Inhibrx's 13 October 2026 press release lists the Phase 2 primary analysis as an oral presentation at ESMO on 25 October 2026. Fuller data on response duration and survival would extend the September headline numbers.
• Analyst targets sit far above the share price. H.C. Wainwright initiated coverage with a Buy rating and a $245 target on 24 August 2026, according to Benzinga. That is the firm's view and predates the change to the Phase 3 timetable.

Bear case

• The development timetable moved back. The 13 August 2026 quarterly filing planned a Phase 3 start in the third quarter of 2026. The 8 September 2026 filing put Phase 3 after the expansion and FDA alignment, and no new start date has been published.
• The efficacy sample is small. The primary analysis covered 63 evaluable patients out of 68 randomized. A 21.8-point response gap in a trial this size can narrow as patients and follow-up accrue.
• The balance sheet leans on lenders. At 30 June 2026 the company reported $176.3M of long-term debt and a $(53.0)M stockholders' deficit, before the July Term C draw. Net loss for the second quarter of 2026 was $36.7M, or $2.34 per share.
• Sell-side coverage is thin and split. Wall Street Zen rated the stock a strong sell on 17 August 2026, against the H.C. Wainwright Buy. The close of $98.19 on 21 October 2026 is 30.8% below the 52-week high of $141.84.

Price setup

The adjusted close on 21 October 2026 was $98.19, against a 52-week high of $141.84. The three-month price change was 20.4%. The RSI stood at 50.4, a neutral reading.

The close of $99.61 on 25 September 2026 sits just above the market, and the $92.76 close of 8 October 2026 marks the recent low among the closes cited here. Shares outstanding are few (15.7M weighted basic and diluted in the second quarter of 2026), so daily moves of 8% to 10% are ordinary. No insider-selling or share-issuance filing has been found since the 8 September 2026 results.

Crowding evidence is limited to the event itself: a scheduled oral presentation falls on Sunday 25 October 2026, so the first trading reaction comes on 26 October 2026.

Catalysts, next 30 days

• ~12 November 2026, est.: Third-quarter 2026 results, estimated from the 13 August 2026 second-quarter report date. The report would update expansion enrollment, cash needs and any draw on the Term D loan tranche.

Elapsed catalysts

• 25 October 2026: HexAgon-HN Phase 2 primary-analysis oral presentation at ESMO, Madrid (8:30 to 10:00 CET). Fuller response and survival data would show whether the 48.3% versus 26.5% gap holds. (passed 12d ago)

What would change the view

The case breaks if the conference data show the response or progression-free-survival lead moving toward the pembrolizumab-only arm, or if the company cancels or delays the HPV-positive Phase 2 expansion or drops the Phase 3 plan. A daily close below $85 would also end it. That level sits below the 8 October 2026 close of $92.76.

A financing that dilutes shareholders, such as a new common-share offering, a Term D draw, or a going-concern statement in the next quarterly filing, would weaken the case. Clean data with a dated enrollment start for the expansion would strengthen it.

What it trades with

Inhibrx trades on its own trial news. Moves follow company disclosures such as the 8 September 2026 results and conference slots more than the oncology sector or the broader market. With a thin share count and a debt-heavy balance sheet, single headlines move the shares more than index direction does.